Ozguroglu M, Kilickap S, Sezer A, Gumus M, et al. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 tri Lancet Oncol 2023 Aug 14:S1470-2045(23)00329.
PMID: 37591293